Literature DB >> 20422321

Comparison of levels of antiretroviral drugs with efficacy in children with HIV infection.

Ana Pilar Nso1, Beatriz Larru, Jose Ma Bellón, Ma José Mellado, Jose Tomás Ramos, Ma Isabel González, María Luisa Navarro, María Angeles Muñoz-Fernández, María Isabel de José.   

Abstract

OBJECTIVE: To determine the prevalence of low and high antiretroviral (ARV) plasma levels and to analyze correlation between ARV concentrations and the appearance of therapeutic failure and toxicity.
METHODS: The authors present here a study evaluating antiretroviral plasma concentrations in HIV infected children on nonnucleoside reverse transcriptase inhibitors and protease inhibitors based therapy. The authors carried out a multicentre, cross-sectional study, including HIV-infected children from five large Hospitals in Madrid, Spain. Clinical, haematological, biochemical and immuno-virological parameters were assessed. Antiretroviral plasma trough levels were performed using a validated high performance liquid chromatography method.
RESULTS: Between April 2006 and April 2008, 129 children were enrolled in the present study, with median treatment duration of 39.2 months. 25.5% of the non-nucleoside reverse transcriptase inhibitors levels were low and 17.6%, high. 27.9% percent of the protease inhibitors levels were low and 12.5%, high. A correlation was found among adequate or high levels of antiretrovirals and normal CD4 percentage and low viral load. Lopinavir/ritonavir plasma levels were correlated with an increase in lipodystrophy. Patients with Tanner stage 1 presented the lowest ARV plasma levels. Full adherence was reported for all the participants by a questionnaire.
CONCLUSION: Many HIV-infected children show ARV plasma levels out of the therapeutic range which demands a child-adjusted approach. However, larger studies are urgently needed in pediatric populations to define optimal reference values.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20422321     DOI: 10.1007/s12098-010-0052-y

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  20 in total

1.  Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography.

Authors:  M Sarasa-Nacenta; Y López-Púa; J Mallolas; J L Blanco; J M Gatell; X Carné
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-06-15

Review 2.  Therapeutic drug monitoring in HIV infection: current status and future directions.

Authors:  David Back; Giorgio Gatti; Courtney Fletcher; Rodolphe Garaffo; Richard Haubrich; Richard Hoetelmans; Michael Kurowski; Andrew Luber; Concepta Merry; Carlo-Federico Perno
Journal:  AIDS       Date:  2002-03       Impact factor: 4.177

3.  Lipodystrophy syndrome in children infected with human immunodeficiency virus.

Authors:  C A Wedekind; D Pugatch
Journal:  Pharmacotherapy       Date:  2001-07       Impact factor: 4.705

4.  Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

Authors:  D Descamps; P Flandre; V Calvez; G Peytavin; V Meiffredy; G Collin; C Delaugerre; S Robert-Delmas; B Bazin; J P Aboulker; G Pialoux; F Raffi; F Brun-Vézinet
Journal:  JAMA       Date:  2000-01-12       Impact factor: 56.272

5.  Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Authors:  C Marzolini; A Telenti; L A Decosterd; G Greub; J Biollaz; T Buclin
Journal:  AIDS       Date:  2001-01-05       Impact factor: 4.177

6.  Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy.

Authors:  C V Fletcher; R C Brundage; R P Remmel; L M Page; D Weller; N R Calles; C Simon; M W Kline
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

7.  The relationship between ritonavir plasma trough concentration and virological and immunological response in HIV-infected children.

Authors:  G Gatti; E Pontali; S Boni; C R De Pascalis; M Bassetti; D Bassetti
Journal:  HIV Med       Date:  2002-04       Impact factor: 3.180

8.  Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children.

Authors:  D Jaquet; M Lévine; E Ortega-Rodriguez; A Faye; M Polak; E Vilmer; C Lévy-Marchal
Journal:  AIDS       Date:  2000-09-29       Impact factor: 4.177

9.  Therapeutic drug monitoring for patients with HIV infection: Children's National Medical Center, Washington DC experience.

Authors:  Steven J Soldin; Natella Y Rakhmanina; Hans M L Spiegel; John L Sever
Journal:  Ther Drug Monit       Date:  2004-04       Impact factor: 3.681

10.  Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations.

Authors:  Félix Gutiérrez; Sergio Padilla; Mar Masiá; Andrés Navarro; Juan Gallego; Ildefonso Hernández; José Manuel Ramos; Alberto Martin-Hidalgo
Journal:  Antivir Ther       Date:  2004-02
View more
  2 in total

1.  Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.

Authors:  Alice Tseng; Michelle Foisy; Christine A Hughes; Deborah Kelly; Shanna Chan; Natalie Dayneka; Pierre Giguère; Niamh Higgins; Cara Hills-Nieminen; Jeff Kapler; Charles J L la Porte; Pam Nickel; Laura Park-Wyllie; Carlo Quaia; Linda Robinson; Nancy Sheehan; Shannon Stone; Linda Sulz; Deborah Yoong
Journal:  Can J Hosp Pharm       Date:  2012-03

2.  Pharmacokinetics of lopinavir determined with an ELISA test in youths with perinatally acquired HIV.

Authors:  Roberta Prinapori; Raffaella Rosso; Antonio Di Biagio; Franca Miletich; Elisa Furfaro; Lucia Taramasso; Francesca Ginocchio; Vania Giacomet; Loredana Nulvesu; Maria Pia Sormani; Irene Schiavetti; Alessio Signori; Laura De Hoffer; Claudio Viscoli
Journal:  Indian J Pediatr       Date:  2013-09-07       Impact factor: 1.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.